Ahboucha S, Jiang W, Chatauret N, Mamer O, Baker G B, Butterworth R F
Neuroscience Research Unit, Université de Montréal, CHUM (Hôpital Saint-Luc), Montreal, QC, Canada.
Neurogastroenterol Motil. 2008 Aug;20(8):949-57. doi: 10.1111/j.1365-2982.2008.01132.x. Epub 2008 May 8.
Hepatic encephalopathy (HE) is a neuropsychiatric complication of both acute and chronic liver failure characterized by progressive neuronal inhibition. Some neurosteroids are potent positive allosteric modulators of the gamma-aminobutyric acid (GABA)-A receptor complex, and 'increased GABAergic tone' has been proposed to explain the neuroinhibition characteristics of HE. Brain levels of the neurosteroids pregnenolone, allopregnanolone and tetrahydrodesoxycorticosterone (THDOC) and the functional status of the GABA-A receptor complex were assessed in rats following portacaval anastomosis (PCA). Effects of indomethacin, an inhibitor of the 3alpha-hydroxysteroid dehydrogenase enzyme involved in neurosteroid synthesis, on PCA rat locomotor activity and brain neurosteroid levels were also assessed. Significant increases of the neurosteroid pregnenolone (2.6-fold), allopregnanolone (1.7-fold) and THDOC (4.7-fold) were observed in brains of PCA rats. Brain levels of these neurosteroids were in the nanomolar range, sufficient to exert positive allosteric modulatory effects at the GABA-A receptor. Indomethacin (0.1-5 mg kg(-1)) ameliorated dose-dependently the locomotor deficit of PCA rats and concomitantly normalized brain levels of allopregnanolone and THDOC. Increased brain levels of neurosteroids with positive allosteric modulatory actions at the neuronal GABA-A receptor offer a cogent explanation for the notion of 'increased GABAergic tone' in HE. Pharmacological approaches using agents that either reduce neurosteroid synthesis or modulate the neurosteroid site on GABA-A receptor could offer new therapeutic tools for the management and treatment of HE.
肝性脑病(HE)是急性和慢性肝衰竭的一种神经精神并发症,其特征为进行性神经元抑制。一些神经甾体是γ-氨基丁酸(GABA)-A受体复合物的强效正性变构调节剂,有人提出“GABA能张力增加”来解释HE的神经抑制特征。在大鼠门腔静脉吻合术(PCA)后,评估了神经甾体孕烯醇酮、别孕烯醇酮和四氢脱氧皮质酮(THDOC)的脑内水平以及GABA-A受体复合物的功能状态。还评估了参与神经甾体合成的3α-羟基类固醇脱氢酶抑制剂吲哚美辛对PCA大鼠运动活性和脑内神经甾体水平的影响。在PCA大鼠的脑中观察到神经甾体孕烯醇酮(2.6倍)、别孕烯醇酮(1.7倍)和THDOC(4.7倍)显著增加。这些神经甾体的脑内水平处于纳摩尔范围,足以在GABA-A受体上发挥正性变构调节作用。吲哚美辛(0.1 - 5 mg kg⁻¹)剂量依赖性地改善了PCA大鼠的运动缺陷,并同时使别孕烯醇酮和THDOC的脑内水平恢复正常。在神经元GABA-A受体上具有正性变构调节作用的神经甾体脑内水平升高,为HE中“GABA能张力增加”的概念提供了有力解释。使用减少神经甾体合成或调节GABA-A受体上神经甾体位点的药物的药理学方法,可能为HE的管理和治疗提供新的治疗工具。